Adherence to topical therapies in actinic keratosis: A literature review

Abstract

Background: Actinic keratosis (AK) is a common skin condition, for which topical therapies are frequently prescribed. This review summarises current understanding of patient adherence and persistence to topical AK treatment by identifying literature relating to measures of adherence and persistence and influencing factors.

Methods: A multi-database literature search was conducted (2004–2015) using key search terms. Supplementary searches of pivotal clinical trials and reference lists of eligible papers were also conducted.

Results: Non-adherence and non-persistence rates varied between real-world studies (10–63% and 23–31%, respectively), with combined non-adherence and non-persistence reported as high as 88%. Methods to calculate adherence and persistence differed between studies. Adherence and persistence were generally higher in clinical trials than clinical practice. Key contributing factors to non-adherence and non-persistence to AK treatment were identified as: treatment duration, severity and persistence of local skin responses and patient confusion over treatment regimens.

Conclusion: The review highlighted a significant evidence gap regarding adherence and persistence to topical AK therapies. Combined, non-adherence and non-persistence may be as high as 88% in clinical practice, highlighting the importance of incorporating contributing factors to patient non-adherence into treatment decisions.

Keywords:

• actinic keratosis
• squamous cell carcinoma in situ
• field therapy
• adherence
• persistence
• topical treatment

Acknowledgements

We thank V. Wolfram from Adelphi Values for performing the literature search and providing medical writing assistance.

Disclosure statement

E. Stockfleth – Speaker, Consultant, Advisory Board; Grants, Honoraria Meda, Leo Pharma and Almirall.

K. Peris – Advisory Board; Honoraria (Leo Pharma, Roche, Meda).

C. Guillen – Advisory Board; Honoraria (Leo Pharma, Meda, Galderma, Almirall).

R. Cerio Speaker; Honoraria (Leo Pharma, Janssen, MSD/Pfizer).

N. Basset-Seguin – Consultant; Honoraria (Leo Pharma).

P. Foley – Advisory Board, Investigator, Speaker; Grants, Honoraria (Abbvie, Janssen, MSD, Pfizer) Advisory Board, Investigator; Honoraria (Amgen). Advisory Board, Consultant, Investigator, Speaker; Honoraria (Novartis). Advisory Board, Consultant, Investigator, Speaker; Honoraria (Eli Lilly). Advisory Board, Investigator; Honoraria (Celgene, BMS). Investigator, Consultant: Honoraria (Roche). Advisory Board, Investigator, Speaker; Honoraria (CSL, GSK). Advisory Board, Consultant, Speaker; Honoraria (Galderma). Advisory Board, Consultant, Investigator, Speaker; Honoraria (Leo Pharma).

J.A. Sanches – Advisory Board; Honoraria (Leo Pharma).

E. Farrington – Employee of Adelphi Values. (Adelphi Values received funding from Leo Pharma for the literature search and medical writing assistance).

M. Lebwohl – Consultant; Honoraria (Leo Pharma, Valeant) Investigator; Grants (Leo Pharma).

Funding information

Funding assistance for writing was provided by Leo Pharma.